@HimaglobinA Profile picture

Hima Atluri, MD

@HimaglobinA

Asst Professor @LurieCancer via @MDAndersonNews, @WashUIMres and @UMKCmedschool I Still waiting on an I-70 World Series I Interested in #MedEd and #Leukemia

Similar User
Bing-nan Zhang photo

@BZhangMD

Curtis Lachowiez photo

@CLachowiez

Hunter Cochran MD photo

@HunterCochranMD

Madhu Eluri, MD photo

@MadhuEluri

Andrew Johns, MD photo

@andrewjohnsmd

Owhofasa Agbedia, MD, MPH, FACP photo

@FasaAgbedia

Kyle Concannon, MD photo

@kyleconcannon4

Anmol Singh, MD photo

@MDanmolsingh

Jin Guo, MD photo

@GuoJin1

Preet Shaikh photo

@PreetShaikh

Justin Lebenthal, MD photo

@JustinLebenthal

Michael Slade, MD photo

@MichaelJSlade

Felix Nguyen photo

@BigCoachF

Ben Fangman, MD photo

@benfangman

Dustin McCurry photo

@dust_im_md

Hima Atluri, MD Reposted

👉👉Last clinic day for Hima @HimaglobinA with us. Will miss her. Wonderful clinician, researcher and colleague. All the very best in your new adventure at @NorthwesternMed 🙏🏽🙏🏽👏👏 cc @doctorpemm @TapKadia @jaltmanmd

Tweet Image 1

Hima Atluri, MD Reposted

Grateful for good friends and great mentors #womeninmedicine

Tweet Image 1
Tweet Image 2

Congratulations to this amazing group! Lucky to know and work with you all 🩷

Tweet Image 1
Tweet Image 2

Hima Atluri, MD Reposted

“Rather than telling the patient to come every day for five days for an IV chemotherapy treatment, we can just prescribe a pill they can take at home,” says our Dr. Nitin Jain. Learn about it here: brnw.ch/21wJVqo @NitinJainMD @TapKadia @HimaglobinA #leukemia #EndCancer


Hima Atluri, MD Reposted

Looking forward to presenting investigator initiated phase 2 trial of time-limited pirtobrutinib + venetoclax + obinutuzumab as frontline Rx for pts with CLL at @EHA_Hematology EHA 2024 @wwierda @MDAndersonNews library.ehaweb.org/eha/2024/eha20…


Hima Atluri, MD Reposted

@sanamloghavi also discussed #MRD in #AML: "Not all MRD is created equally," she said. "Not all the assays are as sensitive. So, you really have to know what you're using and how to interpret the data in the context of the greater picture."

Tweet Image 1

Fantastic unanswered questions in #AML session by @Daver_Leukemia @sanamloghavi @Ramikomrokji @MikkaelSekeres Great discussion focused on importance and optimal sequencing of therapies for patients w AML - particularly those with targetable mutations! #HOPLive24

Tweet Image 1

Hima Atluri, MD Reposted

My takeaway front the #CML session with Dr. Jabbour, @MikkaelSekeres and @drsangeetmd : *our definitions of response (ELN, NCCN) need to be updated * be patient before you switch TKI, allow time for deep molecular response * and most importantly : thank you @mcuban #HOPLive24

Tweet Image 1

Hima Atluri, MD Reposted

Proud mentor alert! Former @WashUIMRes Neha Akkad nailed her presentation on the development and validation of a CTCL specific quality of life tool across stages & a diverse population Looking forward to expanding this effort at other centers. @WashUDerm @amy_musiek @WashUOnc

Tweet Image 1
Tweet Image 2

Hima Atluri, MD Reposted

Happy to share our commentary in @practiceupdate shorturl.at/ipwMN with @HimaglobinA on this very timely and interesting paper on targeting molecular MRD by Ing Soo Tion, Andrew Wei and team in @JCO_ASCO shorturl.at/gCKLS  Thank you @Rfonsi1 for the opportunity…

Tweet Image 1
Tweet Image 2

Had an amazing weekend at the CAR T and bispecifics meeting in San Diego! Thank you @NitinJainMD @NoopurRajeMD and Dr. Neelapu! @_MDEducation @jayastuMD @twitterlessNeha

Tweet Image 1

Hima Atluri, MD Reposted

Excited to be in San Diego for the 2nd annual CAR T and Bispecific meeting Excellent speaker lineup Looking forward to interactive discussion cc Dr Raje @NoopurRajeMD Dr Neelapu @_MDEducation @Ryan_Fitzpatric @ChrisRFlowersMD @bshah

Tweet Image 1

Hima Atluri, MD Reposted

👉👉 Please join tomorrow morning 8am Central time for Hematology Grand Rounds at MDACC on ASH updates in CLL. Zoom link below. Passcode in second slide. Thanks mdacc.zoom.us/j/84909344711?…

Tweet Image 1
Tweet Image 2

Hima Atluri, MD Reposted

Thank you  @AkEisfeld for visiting @MDAndersonNews .. for your outstanding talk on myeloid sarcoma and for sharing your beautiful data with us. Seeing this story come to life has been a true joy. looking forward to ongoing and future exciting collaborations together.

Tweet Image 1
Tweet Image 2

Thank you so much @doctorpemm @sanamloghavi @DanielleHammo20 @HusseinAbbasLab @GhayasIssa @DrHKantarjian @HimaglobinA @NitinJainMD and all of the @MDAndersonNews team for hosting me- such an amazing visit, great discussions & so excited for even more collaborations in the future!



Hima Atluri, MD Reposted

Thank you so much @doctorpemm @sanamloghavi @DanielleHammo20 @HusseinAbbasLab @GhayasIssa @DrHKantarjian @HimaglobinA @NitinJainMD and all of the @MDAndersonNews team for hosting me- such an amazing visit, great discussions & so excited for even more collaborations in the future!

👉👉👉Wonderful Visiting Faculty visit by our great friend & colleague Dr .@AkEisfeld & great talk on AML today at @MDAndersonNews Leukemia Grand Rounds !! Special thanks 🙏 to Dr @sanamloghavi for organizing & facilitating our meeting up! #leusm | @HemeReports

Tweet Image 1


Hima Atluri, MD Reposted

📰Excited to share our latest article! We validated a molecular prognostic risk signature #mPRSc in patients with #AML treated with #HMA and #Venetoclax @sanamloghavi @TapKadia ashpublications.org/bloodadvances/…

Tweet Image 1

Hima Atluri, MD Reposted

Excited to share our latest work now published @NatureComms characterizing the role of IFNg signaling in AML and its implications on AML differentiation, therapy resistance, and immune microenvironment. @BofeiWang3 @HusseinAbbasLab nature.com/articles/s4146…


Hima Atluri, MD Reposted

Acute myeloid leukemia patients with central nervous system involvement “have inferior survival when compared to patients without central nervous system disease,” says our Dr. Hannah Goulart. brnw.ch/21wHeH0 @HealthDayTweets @HannahGoulart #leukemia #EndCancer


Hima Atluri, MD Reposted

👉👉👉Delighted to share our paper in @NEJM ➡️ Results for Ph2 clinical trial of #PTG300 #Rusfertide a novel #HepcidinMimetic for patients with Polycythemia Vera (PV) | #MPNSM | @MKremyanskaya @KuykendallMd @doctorpemm et al @MDAndersonNews #endcancer nejm.org/doi/full/10.10…

Tweet Image 1

Loading...

Something went wrong.


Something went wrong.